Combined Training (Strength and Endurance) and the Serum Levels of Myostatin and Hormone-sensitive Lipase in Overweight and Obese Men
18 juin 2026 mis à jour par: Arya Habibi
Effect of Upper Body and Lower Body Combined Training (Strength and Endurance) on the Serum Levels of Myostatin and Hormone-sensitive Lipase in Overweight and Obese Men
This randomized controlled trial investigated the effects of upper body-based and lower body-based combined training on serum levels of myostatin (MSTN) and hormone-sensitive lipase (HSL) in overweight and obese men. Myostatin is a myokine involved in the regulation of skeletal muscle growth and adipose tissue metabolism, while HSL is a key enzyme involved in lipolysis and fat mobilization.
Thirty-six overweight and obese men were assigned to either an upper body combined training group, a lower body combined training group, or a non-exercising control group. The intervention consisted of 10 weeks of combined resistance and aerobic training performed three times per week. Serum levels of MSTN and HSL were measured before and after the intervention to determine whether upper body-focused and lower body-focused combined training produce different effects on markers associated with muscle growth and lipid metabolism.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Réel)
36
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Tehran Province
-
Tehran, Tehran Province, L'Iran
- Faculty of Sports and Health Sciences of the University of Tehran
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
Oui
La description
Inclusion Criteria:
- Male participants aged 20 to 45 years.
- Body mass index (BMI) ≥25 kg/m².
- Overweight or obese status.
- No participation in regular resistance or aerobic exercise during the previous 6 months.
- Willingness to participate and provide written informed consent.
Exclusion Criteria:
- Presence of metabolic diseases, including diabetes mellitus.
- Presence of cardiovascular or respiratory diseases.
- Musculoskeletal or joint injuries that could interfere with exercise participation.
- Use of anti-obesity medications.
- Use of anabolic steroids, sports supplements, or fat-burning supplements.
- Regular alcohol consumption or tobacco use.
- Absence from more than two training sessions during the intervention period.
- Withdrawal of consent or unwillingness to continue participation.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Upper Body Combined Training
Participants completed a 10-week upper body-focused combined training program three times per week.
Each session consisted of upper body resistance exercises followed by aerobic exercise performed on a hand ergometer.
Resistance training included chest press, rowing machine, biceps curl, triceps extension, shoulder press, and abdominal exercises.
|
Participants completed a 10-week upper body-focused combined training program performed three times per week.
Each session included six upper body resistance exercises (chest press, rowing machine, biceps curl, triceps extension, shoulder press, and abdominal machine exercises) followed by aerobic exercise on a hand ergometer.
Resistance training was performed for 3 sets during the first 5 weeks and 4 sets during weeks 6-10, with 8-12 repetitions per set.
Aerobic exercise began at 20 minutes and increased by 1 minute each week, reaching 29 minutes in the final week.
Exercise intensity was maintained at approximately 57-66% of maximum heart rate during aerobic training.
Autres noms:
|
|
Expérimental: Lower Body Combined Training
Participants completed a 10-week lower body-focused combined training program three times per week.
Each session consisted of lower body resistance exercises followed by aerobic exercise performed on a leg ergometer.
Resistance training included leg press, leg extension, leg flexion, leg abduction, leg adduction, and calf raise exercises.
|
Participants completed a 10-week lower body-focused combined training program performed three times per week.
Each session included six lower body resistance exercises (leg press, leg extension, leg flexion, leg abduction, leg adduction, and calf raise exercises) followed by aerobic exercise on a leg ergometer.
Resistance training was performed for 3 sets during the first 5 weeks and 4 sets during weeks 6-10, with 8-12 repetitions per set.
Aerobic exercise began at 20 minutes and increased by 1 minute each week, reaching 29 minutes in the final week.
Exercise intensity was maintained at approximately 57-66% of maximum heart rate during aerobic training.
Autres noms:
|
|
Aucune intervention: Control
Participants in the control group did not participate in the exercise intervention and were instructed to maintain their usual daily activities throughout the 10-week study period.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in serum myostatin (MSTN) concentration
Délai: Baseline and 10 weeks
|
Serum myostatin concentration measured by enzyme-linked immunosorbent assay (ELISA).
The outcome was assessed before the intervention and 48 hours after completion of the 10-week training program.
|
Baseline and 10 weeks
|
|
Change in serum hormone-sensitive lipase (HSL) concentration
Délai: Baseline and 10 weeks
|
Serum hormone-sensitive lipase concentration measured by enzyme-linked immunosorbent assay (ELISA).
The outcome was assessed before the intervention and 48 hours after completion of the 10-week training program.
|
Baseline and 10 weeks
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
1 mai 2024
Achèvement primaire (Réel)
1 mai 2024
Achèvement de l'étude (Réel)
15 décembre 2024
Dates d'inscription aux études
Première soumission
14 juin 2026
Première soumission répondant aux critères de contrôle qualité
14 juin 2026
Première publication (Réel)
18 juin 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
23 juin 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
18 juin 2026
Dernière vérification
1 juin 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IR.UT.SPORT.REC.1403.064
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Description du régime IPD
Individual participant data (IPD) will not be made publicly available.
The study was not originally designed with a formal data-sharing plan, and participant-level data contain information that could potentially compromise participant confidentiality.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .